NAPLES, Fla., March 29, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a neuroscience company developing next-generation, psychedelic-inspired mental health medicines, announces the filing of a provisional patent application based on…
https://endpts.com/inside-the-race-to-make-psychedelics-mainstream-medicines/
https://www.benzinga.com/markets/cannabis/22/03/26284541/five-companies-developing-second-generation-psychedelics-for-mental-health
Patent Applications Aim to Expand Opportunities for Novel Therapeutics to Address a Broad Range of Psychiatric and Neurological Disorders NAPLES, Fla., March 15, 2022 /CNW/ – Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or…
NAPLES, Fla., March 3, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines, today announced that Dr. Joseph Tucker, Chief Executive Officer of…
Robust Portfolio of Psychedelic-Inspired Molecules Positions Enveric to Achieve Global Patent Protection to potentially Cover Millions of Novel Pharmaceutical Candidates NAPLES, Fla., March 1, 2022 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”),…
Groundbreaking trial to explore psychedelic therapy for cancer distress
Clinical trial aim is to include the identification and characterization of the Cancer Related Distress symptoms most responsive to psychedelic-associated therapy NAPLES, Fla., Feb. 17, 2022 /CNW/ – Enveric Biosciences (NASDAQ: ENVB)(“Enveric” or…
https://www.benzinga.com/markets/cannabis/22/02/25697576/psilocybin-for-cancer-related-distress-enveric-to-launch-clinical-trial-in-partnership-with-univ